10-Q: DLH Holdings Corp. Reports Increased Revenue and Net Income in Q2 2024

Sentiment:

Quarterly Report


DLH Holdings Corp. saw revenue and net income growth in the second quarter of 2024, driven by public health and IT services.

Delay expectedThe VA has delayed the award of new contracts for healthcare logistics and pharmacy services, and DLH continues to operate under a sole-source IDIQ contract.
Better than expectedThe company's net income for the quarter was significantly higher than the same period last year.The company's revenue for the quarter was higher than the same period last year.The company's net income for the six months was significantly higher than the same period last year.The company's revenue for the six months was significantly higher than the same period last year.

Summary

  • DLH Holdings Corp. reported a revenue of $101.0 million for the three months ended March 31, 2024, compared to $99.4 million for the same period in 2023.
  • Net income for the quarter was $1.8 million, a significant increase from $0.8 million in the prior year.
  • For the six months ended March 31, 2024, revenue reached $198.9 million, up from $172.2 million in 2023.
  • The company's net income for the six-month period was $4.0 million, compared to $2.4 million in the previous year.
  • The increase in revenue was primarily due to growth in public health and IT services, partially offset by national security contracts converting to small business set-asides.
  • The company's backlog was $736.2 million as of March 31, 2024, with $106.9 million funded.

Sentiment

Score: 7

Explanation: The document shows positive financial results with increased revenue and net income, but there are some risks and uncertainties related to government contracts and debt management. The sentiment is cautiously optimistic.

Positives

  • The company experienced revenue growth in both the three and six-month periods ending March 31, 2024.
  • Net income significantly increased for both the three and six-month periods.
  • The company's backlog remains strong at $736.2 million.
  • EBITDA increased to $21.3 million for the six months ended March 31, 2024, from $16.8 million in the prior year.
  • The company made voluntary prepayments of $5.9 million on its secured term loan during the six months ended March 31, 2024.

Negatives

  • General and administrative costs increased to 11.6% of revenue from 10.8% in the three months ended March 31, 2024.
  • Interest expense increased by $2.3 million for the six months ended March 31, 2024, compared to the same period in 2023.
  • The company's cash balance is relatively low at $0.2 million as of March 31, 2024.
  • The company is dependent on a few major customers for a significant portion of its revenue.

Risks

  • The company is subject to risks associated with government contracts, including bid protests and termination risks.
  • Changes in client budgetary priorities could negatively impact the company's revenue.
  • The company faces competition for new business and re-competes for existing contracts.
  • The company's ability to manage its increased debt obligations is a risk.
  • The company must comply with bank financial and other covenants.
  • The company is subject to the impact of inflation and higher interest rates.
  • Federal contractual set-aside laws and regulations may limit the company's ability to compete for prime contractor positions.

Future Outlook

The company aims to expand its position as a trusted provider of technology-enabled healthcare and public health services, medical logistics, and readiness enhancement services. The company is also focused on expanding within top national priority programs and funded areas.

Management Comments

  • The company is focused on expanding its position as a trusted provider of technology-enabled healthcare and public health services.
  • The company is leveraging multiple capabilities, including cyber technology, artificial intelligence, advanced analytics, cloud-based applications, and telehealth systems.
  • The company believes its service excellence over many years on the VA program would provide an advantage in any competition.

Industry Context

The company operates in the government contracting sector, providing services to various federal agencies. The report highlights the importance of digital transformation, cybersecurity, and public health initiatives, which are key areas of focus for the government. The company's performance is influenced by federal budget allocations and procurement policies.

Comparison to Industry Standards

  • DLH's revenue growth of 1.6% for the three months ended March 31, 2024, is modest compared to some high-growth technology companies in the government contracting space, but is solid for a company focused on government services.
  • The company's EBITDA margin of approximately 10.7% for the six months ended March 31, 2024, is within the typical range for government contractors, but could be improved.
  • Companies like Booz Allen Hamilton and Leidos, which are larger and more diversified, often have higher revenue and EBITDA figures, but DLH is focused on specific niches within the government sector.
  • DLH's reliance on a few major customers is a common characteristic of government contractors, but diversification is often a goal to reduce risk.
  • The company's backlog of $736.2 million is a positive indicator of future revenue, but the conversion of backlog to revenue is subject to government funding cycles and contract performance.

Stakeholder Impact

  • Shareholders will likely view the increased revenue and net income positively.
  • Employees may benefit from the company's growth and stability.
  • Customers will continue to receive services from the company.
  • Suppliers and creditors will be impacted by the company's financial performance.

Next Steps

  • The company will continue to pursue its remedies under the Federal acquisition regulations regarding the Chelmsford CMOP contract award.
  • The company will continue to operate under the sole-source IDIQ contract awarded by the VA.
  • The company will continue to monitor the federal budget outlook for fiscal year 2025.

Key Dates

DateDescription
September 19, 2019The company executed a floating-to-fixed interest rate swap with First National Bank.
December 8, 2027Maturity date for the secured term loan and secured revolving line of credit.
January 31, 2023The company executed an additional floating-to-fixed interest rate swap with First National Bank.
April 30, 2024Bridge contracts for VA pharmacy and logistics services expired.
May 1, 2024Effective date of the sole-source IDIQ contract awarded by the VA.
June 7, 2024Maturity date of the first interest rate swap.
July 31, 2024Initial task orders for the VA IDIQ contract expire.
January 31, 2026Maturity date of the second interest rate swap.

Keywords

government contracts, healthcare, cybersecurity, information technology, public health, digital transformation, research and development, systems engineering, federal government, EBITDA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.